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original report

Symptom Levels in Care-Seeking
Bangladeshi and Nepalese Adults With
Advanced Cancer
abstract

Purpose Three-fourths of patients with advanced cancer are reported to suffer from pain. A primary barrier
to provision of adequate symptom treatment is failure to appreciate the intensity of the symptoms patients
are experiencing. Because data on Bangladeshi and Nepalese patients’ perceptions of their symptomatic
status are limited, we sought such information using a cell phone questionnaire.
Methods At tertiary care centers in Dhaka and Kathmandu, we recruited 640 and 383 adult patients,
respectively, with incurable malignancy presenting for outpatient visits and instructed them for that single
visit on one-time completion of a cell phone platform 15-item survey of questions about common cancerassociated symptoms and their magnitudes using Likert scales of 0 to 10. The questions were taken from the
Edmonton Symptom Assessment System and the Brief Pain Inventory instruments.

Richard Reed Love
Tahmina Ferdousy

Results All but two Bangladeshi patients recruited agreed to study participation. Two-thirds of Bangladeshi
patients reported usual pain levels ‡ 5, and 50% of Nepalese patients reported usual pain levels ‡ 4
(population differences significant at P < .001).

Shamsun Nahar

Conclusion Bangladeshi and Nepalese adults with advanced cancer are comfortable with cell phone
questionnaires about their symptoms and report high levels of pain. Greater attention to the suffering of
these patients is warranted.
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INTRODUCTION
Three-fourths of patients with advanced cancer
are reported to suffer from pain,1 and “85% of
patients with pain can be well palliated with the
use of simple, inexpensive, ‘low technology’ oral
analgesics.”2(p715) A primary barrier to provision of
adequate treatment of symptoms is failure to appreciate the intensity of the symptoms patients are
experiencing.2 To provide optimal care for patients
with cancer, accurate, complete, and timely information about symptoms—daily information if
possible—is necessary. In particular, failure to use
(repeatedly) validated symptom assessment tools
prevents communication between patients and
health care providers to bring attention to symptom issues.3 The usual way such information is
obtained is through direct questioning or information provided by patients in paper questionnaires
during patients’ office visits with medical practitioners. Such visits can rarely be daily. For patients
with cancer, the most widely used questionnaire
for this task is the Edmonton Symptom Assessment Survey.4 This is a 10-question instrument
that is usually answered by patients on paper.
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Because pain is the most common distressing
symptom for patients with cancer, a second instrument with more detailed questions about pain
(worst [highest] level, best [lowest] level, and
usual level in the last 24 hours)—the Brief Pain
Inventory—is often used.5 Common practice is to
have patients provide answers on paper to these
instruments when they are seen in doctors’ offices. A
more abbreviated symptom assessment strategy in
doctor-patient encounters is simply to have patients
verbally report their current level of pain using a visual
analog scale of 0 to 10. However, this is a one-time
and one-item assessment strategy. In an ideal situation, to monitor patients more completely, know
how patients feel every day, and then make adjustments in treatments (such as types, amounts, and
timing of pain medicines), it would be good to have
data from such questionnaires every day. One even
more practical way to make obtaining such detailed
symptom information possible and usable by physicians is to put the questionnaires on a cell phone
software platform, which the patient or his/her attendant could then complete at home and send by
phone each day to a doctor’s records and/or office.
jgo.org JGO – Journal of Global Oncology
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Data on narcotic medication consumption in Bangladesh and Nepal show low consumption levels,
which would suggest that pain control among
patients with advanced cancer in these countries
is likely to be poor. This conclusion characterized
the recent Economist Intelligence Unit Quality of
Death Index evaluation, in which Bangladesh was
ranked 79th out of 80 countries (Nepal was not
ranked).6,7 Although long- and short-acting morphine are available in Bangladesh, access is limited to few pharmacies, and few physicians are
comfortable using these drugs. In Nepal, opioids
are available but accessible only in major cities,
and again, only a minority of physicians are comfortable with their use. There are, however, limited
published data about the symptomatic status of
such patients. In these overall contexts, then, as
part of a study evaluating the feasibility of using a
cell phone platform questionnaire to obtain symptom status information, we have obtained such
data from . 1,000 Bangladeshi and Nepalese
outpatients with advanced cancer.
METHODS
We have taken items from the open source
Edmonton Symptom Assessment Survey (nine
of 10 items: nausea, tiredness, depression, anxiety, drowsiness, appetite, well-being, shortness of
breath, and current pain; the “other problem” item
was omitted) and Brief Pain Inventory (three
items: worst, least, and usual levels of pain in last
24 hours) validated questionnaires, added three
items (constipation, quantity of sleep, and quality
of sleep) because these are standard questions
that palliative care physicians ask of patients, and
put these 15 questions on a cell phone platform in Bangla (the native language of Bengal/
Bangladesh) and Nepali. In , 3 minutes, patients
can answer the questions by moving a cursor
along visual analog scale bars (0 to 10) to indicate
intensities of their symptoms. The cell phone program has the questions in both written and audio
form, so that patients who cannot read or with
impaired vision or poor visual acuity can also
answer the questions. We have piloted this application with several patients and made adjustments to make sure the instrument presented in
this form is easy to understand and use.
After obtaining appropriate scientific and ethical
review board approvals in Bangladesh, Nepal, and
the United States, at two tertiary care clinical sites
in Bangladesh, and at three sites in Nepal, at the
time of presentation for outpatient visits, we recruited adult patients with advanced incurable
cancer who had normal mental status; performance

258 Volume 3, Issue 3, June 2017

status 0, 1, 2, or 3 on the Eastern Cooperative
Oncology Group scale; ability to understand and
cooperate with the study protocol, including cell
phone operation; and willingness to participate and
provide written informed consent. At the time of one
single visit, each participant privately completed the
instrument using a smart phone with the application
provided by—and after training by—a research
assistant. The research assistant did not look at
or share individual patients’ data. The data collected by the cell phone application were sent
via a secure connection to a cloud server database. They were then accessed for analysis over a
secure connection by a team at Marquette University. Occasionally there were network delays or power
outages that prevented immediate transmission of
the questionnaire data to the cloud, but otherwise
all data transmission was successfully accomplished.
The data were collected with some interruptions
between April 2013 and August 2014.
RESULTS
Two patients of 642 individuals approached in
Bangladesh and no patients of 383 patients in
Nepal refused study participation. The distributions of the most common primary cancer types
among the 286 Bangladeshi men (45%) and 354
Bangladeshi women (55%) and the 182 Nepalese
men (47%) and 205 Nepalese women (53%) are
shown in Table 1. Compared with the estimated
major cancer incidences and causes of death in
Bangladesh, colorectal cancer in men is modestly
over-represented, breast cancer in women is overrepresented, and cervical cancer in women is
under-represented. Similar comparisons for Nepalese suggest that colorectal cancer and prostate
cancer are slightly over-represented in men, and
breast and colorectal cancers are slightly overrepresented in women. Thirty-eight percent of
Bangladeshi patients were < 40 years old, and
19% of the Nepalese patients were in this age
group.
Data for the four pain scores—average, maximal,
minimum, and current—showed the following.
Average/usual pain scores for Bangladeshis
were > 5 in 64%; in Nepalese they were > 5 in
27% and , 4 in 50%. Maximal pain scores for
Bangladeshis were > 5 in 67%; in Nepalese they
were > 5 in 60%. There were no maximal pain
scores of 9 or 10 in Bangladeshis. Minimum pain
scores for Bangladeshis were > 5 in 20%; in
Nepalese they were > 5 in 7%. Current pain
scores in Bangladeshis were > 5 in 74%; in
Nepalese they were > 5 in 52%. For the Bangladesh data, if we assume the population mean pain
jgo.org JGO – Journal of Global Oncology
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Table 1. Major Primary Cancer Types Among Bangladeshi and Nepalese Patients Questioned About Their Symptoms
Bangladeshis
Men (n = 286)
Lung, 53 (19)

Nepalese
Women (n = 354)
Breast, 99 (28)

Men (n = 182)
Lung, 48 (26)

Women (n = 205)
Breast, 52 (25)

Lymphomas, 47 (16)

Lung, 34 (10)

Head and neck, 46 (25)

Cervix, 32 (16)

Colorectal, 41 (14)

Ovary, 27 (8)

Stomach, 19 (10)

Lung, 22 (11)

Stomach, 21 (7)

Colorectal, 26 (7)

Lymphomas, 15 (8)

Ovary, 18 (9)

Head and neck, 21 (7)

Cervical, 19 (5)

Colorectal, 13 (7)

Colorectal, 14 (7)

Liver, 19 (7)

Lymphomas, 19 (5)

Prostate, 9 (5)

Stomach, 12 (12)

NOTE. Data presented as No. (%).

level is 5, then the T score = 2.125, with degrees
of freedom (DOF) = 639 and P value = .0339.
For the Nepal data, if we assume the population
mean pain level is 5, then the T score = 23.2596,
with DOF = 382 and P value = .0012. Testing then
for differences in pain values of the two populations
together, the T score = 23.8568, with DOF = 1,021
and P value , .001, suggesting that the two populations are significantly different in the levels of
current pain. An analysis for usual or average pain
showed similar results.
Average or usual pain score levels seemed to
provide the highest correlations with other pain
scores in both Bangladeshi and Nepalese populations. For Bangladeshis, scores for nausea, anxiety,
loss of appetite, and sleep quality each showed
correlations > 0.74 with current pain levels. Scores
in both country populations for men and women
for all items were similar, and scores for the most
common cancer types—lung in men and breast in
women—were no different from those for all other
cancers combined.
DISCUSSION
The first striking observation from our study is that
in both countries essentially all patients were
willing to and could provide data about their symptoms using a cell phone platform and did this
successfully. This suggests that longitudinal repeated assessment using this cell phone application in these settings may be possible and that
acceptance of such technology is high. In the
settings of Bangladesh and Nepal, where there
are no hospice services, the potential for use of
such cell phone reporting to allow remote management is real and worthy of exploration.
In interpreting and attaching significance to specific data in this study, certain limitations should
first be noted. We have recruited convenience
samples; our data are from patients able to present to tertiary care facilities by dint of economic
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resources, location, and their nonterminal performance status. It is reasonable to suggest that our
study subjects might, if anything, be better off (less
symptomatic) than those in population-based
samples in both countries. Demographically, our
Bangladeshi patients were younger than the Nepalese patients and less representative of a normal
population of patients with cancer, which would be
expected to be older. How much the skewed
percentages of types of cancer from those expected in the population generally might have
affected the broad characteristics of the symptom
data is uncertain but would seem to be small.
These limitations noted, our data suggest first that,
as expected, Bangladeshi and Nepalese patients
with advanced cancer are generally significantly
affected with pain. Maximal and current pain
scores were > 5 in the majority of patients from
both countries. As in other countries, these specific data are consistent with the low levels of
narcotic drug consumption and now should justify
greater attention to symptom and pain management in such patients.6 Second, of possible clinical interest is that although higher Bangladeshi
than Nepalese patient scores for pain may of
course reflect the composition of the populations
studied, it is possible that there are significant
cultural differences in how these populations perceive their discomfort. In this study we did not
share individual patients’ data with their treating
physicians, because in the circumstances in
which the data were obtained this was not practical
or, possibly, appropriate. Consequently, we could
have no data on possible impact of this information
on immediate patient care.
In conclusion, Bangladeshi and Nepalese adults
with advanced cancer able to seek outpatient care
are comfortable with cell phone questionnaires
and report high levels of pain. Greater attention to
the suffering of these patients is warranted, and
the use of a cell phone application offers a
jgo.org JGO – Journal of Global Oncology
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mechanism for real-time, daily or more frequent,
monitoring of levels of symptoms.
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